• Rucaparib in DNA Damage Response Research

  2026-09-02

  Rucaparib (AG-014699) is a potent PARP1 inhibitor for testing how impaired base excision repair, homologous recombination defects, and NHEJ suppression shape cancer-cell sensitivity. This workflow-focused guide covers stock preparation, radiosensitization assays, orthogonal DNA-damage readouts, and troubleshooting for reproducible cancer biology research.

• PPACK Dihydrochloride: From Thrombin to Thrombus

  2026-09-01

  PPACK Dihydrochloride offers translational researchers a high-affinity, irreversible way to isolate thrombin-dependent biology from platelet purinergic signaling. Paired with the NF449 reference study, it supports a more precise framework for interpreting thrombin inhibition assays, platelet aggregation inhibition, and blood coagulation research.

• Lopinavir: From HIV Potency to Assay Design

  2026-09-01

  Lopinavir and ABT-378 are examined through an assay-centered framework that connects HIV protease potency with cell-based antiviral interpretation. Learn how resistance controls, serum conditions, formulation, and cross-virus evidence shape rigorous HIV infection research.

• ZK53: Turning Mitochondrial Stress into Strategy

  2026-08-31

  ZK53 is a selective human mitochondrial serine protease ClpP activator that connects mitochondrial proteostasis, tumor-cell stress, DNA-damage signaling, and ferroptosis sensitivity.

• M344: Histone Deacetylase Inhibitor Guide

  2026-08-31

  M344 is a cell-permeable histone deacetylase inhibitor with a product-reported IC50 of 100 nM. It is a research tool for HDAC-mediated chromatin regulation, cancer-cell growth studies, differentiation experiments, radiation-response models, and HIV-1 latency research.

• Phillygenin Mechanisms in Diabetic Nephropathy

  2026-08-30

  A 2025 Phytomedicine study shows that phillygenin protects against diabetic nephropathy in high-glucose podocytes and db/db mice by coordinating suppression of TLR4/MyD88/NF-κB inflammation with support of PI3K/AKT/GSK3β signaling. The work links reduced cytokine production and apoptosis to improved albuminuria and renal injury, while also defining important limits for translating pathway-level findings into therapeutic practice.

• JAK Inhibitors and RA Sensory Neuron Activation

  2026-08-29

  This preprint identifies a direct effect of rheumatoid arthritis synovial fluid on human sensory neurons and shows that JAK inhibition can block associated STAT3 signaling and pain-relevant transcriptional responses. The findings provide a mechanistic hypothesis for the analgesic effects of JAK inhibitors, while also highlighting the value of combining patient-derived fluids, iPSC-derived neurons, transcriptomics, and functional neuronal assays.

• Ganetespib: From Hsp90 to Translational Strategy

  2026-08-28

  A mechanistic and strategic framework for using Ganetespib (STA-9090) in cancer research, integrating Hsp90 client-protein degradation, tumor growth inhibition, assay design, and carefully bounded insights from NINJ1-mediated viral protein secretion.

• Z-VEID-FMK Workflow for Caspase-6 Studies

  2026-08-28

  Z-VEID-FMK offers a cell-permeable, irreversible way to test whether caspase-6 drives apoptotic substrate cleavage, rather than merely correlating with cell death. This workflow translates that mechanism into practical designs for neuronal apoptosis research, immune-cell models, and exploratory antiviral experiments involving the DDX23–SVA axis.

• Thymoquinone Workflows for Cardiotoxicity

  2026-08-27

  Build a practical thymoquinone workflow for modeling doxorubicin-induced cardiac injury with matched redox, ferroptosis, mitochondrial, and functional readouts. The approach translates a mouse cardioprotection study into formulation guidance, assay controls, and troubleshooting decisions for cell and preclinical research.

• MOG (35-55) for EAE and MS Research

  2026-08-27

  MOG (35-55) provides a practical, highly encephalitogenic platform for modeling autoimmune neuroinflammation and evaluating multiple sclerosis interventions. This guide connects peptide handling and EAE workflow design with STAT1/STAT2 signaling, PARP7 biology, and assay-level troubleshooting.

• A-1331852: Mapping BCL-XL Apoptotic Dependence

  2026-08-26

  A-1331852 is a selective BCL-XL inhibitor for dissecting mitochondrial apoptosis, cellular senescence, and treatment resistance. This guide translates BH3-mimetic evidence into practical apoptosis assay decisions while distinguishing direct compound data from broader biological inference.

• Cefotaxime as a Probe of Resistance Architecture

  2026-08-26

  Cefotaxime can serve as more than a selectable antibiotic: it provides a mechanistic and translational lens for connecting beta-lactam activity, resistance genes, plasmid mobility, and bacterial infection model design. This article interprets recent carbapenem-resistant Enterobacter cloacae findings and translates them into practical guidance for antimicrobial resistance research while defining the compound’s limits.

• Sulfo-NHS-SS-Biotin for CAR-T Surface Profiling

  2026-08-25

  Sulfo-NHS-SS-Biotin enables reversible labeling of extracellular primary amines, making it useful for CAR-T surface proteomics, affinity enrichment, and cleanup-sensitive protein workflows. Its water-compatible chemistry and cleavable disulfide spacer help distinguish accessible surface proteins from intracellular material while supporting downstream release with reducing conditions.

• FPH1 (BRD-6125) Hepatocyte Assay Guide

  2026-08-25

  FPH1, also called BRD-6125, is a small molecule reported to promote functional proliferation in primary human hepatocytes and improve functional markers in iPSC-derived hepatocyte-like cells. The product dossier supports a focused workflow using 20 μM FPH1 on days 1 and 5, while emphasizing that proliferation and hepatocyte function require separate readouts.

8117 records 1/542 page Next 12345 下5页 Last page